@article{5c13a2466bc143c79de2bfb5426be386,
title = "Paving the way to precision medicine in multiple myeloma",
keywords = "BCL2, Venetoclax, apoptosis, multiple myeloma, precision medicine, targeted therapy",
author = "Shafqat Inam and Ross, {Jeremy A.} and Cyrille Touzeau and Philippe Moreau and Kumar, {Shaji K.} and Harrison, {Simon J.}",
note = "Funding Information: S Harrison receives consultancy fees from, is on the advisory board for and an investigator for Abbvie; Celgene and Janssen; receives honoraria and research funding from Celgene and Janssen. J Ross has employment with AbbVie and may hold stock or other options. P Moreau receives consultancy and honoraria fees from Sanofi, Janssen, Amgen, Celgene/Bristol-Myers Squibb and Abbvie; honoraria from Takeda and Novartis. SK Kumar receives Research funding for clinical trials to the institution from Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Medimmune, Novartis, Roche-Genentech, Takeda, and Tenebio; is on the consulting/advisory board for (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda; and (with personal payment) Oncopeptides, Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ",
year = "2021",
doi = "10.1080/17474086.2021.1905515",
language = "English (US)",
volume = "14",
pages = "323--327",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "4",
}